Roivant Sciences (ROIV): Director reported a transaction in 33K shares
Mayukh Sukhatme, Director at Roivant Sciences, reported a transaction of 33K shares.
- 33K
- Shares · @ $23.09
- Traded
- Dec 17, 2025
- Filed
- Dec 20, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Oct 15, 2025InsiderCEO sold ~$7.02M of ROIV shares in the open market
- Oct 16, 2025InsiderCEO sold ~$5.43M of ROIV shares in the open market
- Oct 17, 2025InsiderCEO sold ~$2.02M of ROIV shares in the open market
- Oct 30, 2025Congress · 1 personMembers of Congress: 1 purchase, 1 sale
- Oct 31, 2025CongressDisclosed sale of ROIV — reported range $1,001 - $15,000
- Nov 7, 2025InsiderCEO sold ~$4.04M of ROIV shares in the open market
- Nov 10, 2025Company filing · Form 8-K · ResultsReported its results
- Nov 13, 2025Insider10% owner sold ~$5.98M of ROIV shares in the open market
- Nov 14, 2025Insider10% owner sold ~$20.9M of ROIV shares in the open market
- Nov 17, 2025Insider10% owner sold ~$11.1M of ROIV shares in the open market
- Nov 19, 2025Insider · 3 peopleInsiders: 12 sales (~$78.9M)
- Dec 9, 2025InsiderCEO sold ~$4.17M of ROIV shares in the open market
- Dec 11, 2025Insider10% owner sold ~$16.8M of ROIV shares in the open market
- Dec 12, 2025Insider · Their largest sale since 202310% owner sold ~$43.4M of ROIV shares in the open market
- Dec 15, 2025Insider · 2 peopleInsiders: 4 sales (~$45.5M)
- Dec 16, 2025Insider · 3 peopleInsiders: 6 sales (~$63.4M)
- Dec 17, 2025Insider · 4 peopleInsiders: 10 sales (~$54.4M)
What came next
- Dec 23, 2025Insider · 2 peopleInsiders: 3 sales (~$13.6M)
- Dec 24, 2025InsiderCEO sold ~$1.69M of ROIV shares in the open market
- Dec 29, 2025InsiderDirector sold ~$6.78M of ROIV shares in the open market
- Dec 31, 2025Insider · Their largest sale since 2024Director sold ~$22.1M of ROIV shares in the open market
- Jan 12, 2026InsiderCEO sold ~$4.38M of ROIV shares in the open market
- Feb 6, 2026Company filing · Form 8-K · ResultsReported its results
- Feb 9, 2026InsiderDirector sold ~$8.99M of ROIV shares in the open market
- Feb 11, 2026Insider · 3 peopleInsiders: 3 sales (~$34.0M)
- Feb 12, 2026Insider · 3 peopleInsiders: 6 sales (~$34.1M)
- Feb 13, 2026Insider · 4 peopleInsiders: 7 sales (~$35.2M)
- Feb 19, 2026InsiderChair sold ~$38.4M of ROIV shares in the open market
- Feb 20, 2026InsiderChair sold ~$27.5M of ROIV shares in the open market
- Feb 23, 2026InsiderChair sold ~$16.2M of ROIV shares in the open market
- Mar 3, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors (and 1 more item)
- Mar 3, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
- Mar 16, 2026InsiderDirector sold ~$1.2M of ROIV shares in the open market
- Mar 17, 2026InsiderCEO sold ~$5.65M of ROIV shares in the open market
- Mar 26, 2026Insider · 7 days before resultsDirector sold ~$1.92M of ROIV shares in the open market
- Apr 2, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
- Apr 8, 2026InsiderOfficer sold ~$384K of ROIV shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Roivant Sciences
For Roivant Sciences, OQRO holds 58 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ROIV page.
Other recent filings by Mayukh Sukhatme, President & CIO
- SEC Form 4 at Roivant Sciences (ROIV)Aug 22, 2026
- SEC Form 4 at Roivant Sciences (ROIV)Aug 22, 2026
- SEC Form 4 at Roivant Sciences (ROIV)Aug 22, 2026
- SEC Form 4 at Roivant Sciences (ROIV)Aug 19, 2026
- SEC Form 4 at Roivant Sciences (ROIV)Aug 19, 2026
The full history of Mayukh Sukhatme, President & CIO is on the profile page.
How this filing works
Explore the data
Common questions
Which Roivant Sciences (ROIV) insider traded, and how much?
Mayukh Sukhatme, Director at Roivant Sciences, reported a transaction of 33K shares. At $23.09.
When did it happen, and when was it made public?
Traded: Dec 17, 2025. Filed: Dec 20, 2025. That is 3 days between the two dates.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Roivant Sciences recently?
For Roivant Sciences, OQRO holds 58 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the ROIV page.
Does this mean ROIV stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Roivant Sciences
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
Everything OQRO holds on this company is on its ROIV page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
